Show simple item record

dc.contributor.authorKucukkaraduman, Baris
dc.contributor.authorTurk, Can
dc.contributor.authorFallacara, Anna L
dc.contributor.authorIsbilen, Murat
dc.contributor.authorSenses, Kerem M
dc.contributor.authorAyyildiz, Zeynep O
dc.contributor.authorAkbar, Muhammad W
dc.contributor.authorLotem, Michal
dc.contributor.authorBotta, Maurizio
dc.contributor.authorGure, Ali O
dc.description.abstractMelanoma is a highly aggressive cancer with poor prognosis. Although more than 80% of melanomas harbor an activating mutation in genes within the MAPK pathway, which are mutually exclusive, usefulness of therapies targeting MAPK pathway are impeded by innate and/or acquired resistance in most patients. In this study, using melanoma cells, we report the efficacy of a recently developed pyrazolo[3,4-]pyrimidine derived c-Src inhibitor 10a and identify a molecular signature which is predictive of 10a chemosensitivity. We show that the expression of TMED7, PLOD2, XRCC5, and NSUN5 are candidate biomarkers for 10a sensitivity. Although an undifferentiated/mesenchymal/invasive status of melanoma cells is associated with resistance to 10a, we show here for the first time that melanoma cells can be sensitized to 10a via treatment with valproic acid, a histone deacetylase inhibitor.en_US
dc.publisherTıp Fakültesien_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.titlePredictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.en_US
dc.contributor.departmentTemel Tıp Bilimlerien_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess